ME
Mikhail Eydelman (SVP, GEN COUNSEL & CORP SEC) filed 4 Form 4 reports in the past 24 months (0 purchases, 4 sales), most often in Vaxcyte, Inc. (PCVX). The largest single filing was $421K of PCVX (4,612 sh across 2 lots, as filed), executed Dec 5 2024. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
4
0 buys · 4 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.4M
shares × price, as filed
Last traded
Mar 5 2025
Filed Mar 7 2025
Median ADV $87.6M across their filed names
Open performance→Volume by month
Buys $0
Sells $1.4M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
4 filings
Sector per market data · by filing · past 24 months
Most traded names
PCVXRecent filings
PCVXSALE
Vaxcyte, Inc.
View filing →
$346K4,888 sh across 2 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. View filing → $320K
3,539 sh across 2 lots
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. View filing → $336K
3,921 sh × $85.73
Exec Jan 6 2025
Filed Jan 7 2025 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. View filing → $421K
4,612 sh across 2 lots
Exec Dec 5 2024
Filed Dec 9 2024 · 5:30 PM ET PCVXSALE Vaxcyte, Inc. View filing → $449K
4,212 sh across 3 lots
Exec Nov 5 2024
Filed Nov 6 2024 · 5:30 PM ET